PHILADELPHIA, PA / ACCESSWIRE / November 8, 2024 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Revance Therapeutics Inc. ("Revance" or the "Company") (NASDAQ:RVNC).
INVESTORS OF REVANCE STOCK WITH FINANCIAL LOSSES CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.
On September 23, 2024, Revance announced, among other things, that it ". . . received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA . . . dated January 10, 2020 . . .."
On this news, the stock of Revance dropped more than 7% closing at $5.365 per share on September 23, 2024.
REVANCE INVESTORS WITH FINANCIAL LOSSES ALSO CAN CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE REVANCE SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.
Kehoe Law Firm, P.C. is a multidisciplinary, plaintiff-side class action law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm, P.C. have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.
This press release may constitute attorney advertising.
SOURCE: Kehoe Law Firm P.C.